We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Rates of patency and device-related thrombus were ...

Please provide your email address to receive an email when new articles are posted on . A next-generation LAA closure device gained FDA approval to reduce risk for stroke in patients non-valvular AF.

VIENNA, AUSTRIA — Thrombi were sometimes found on two left-atrial-appendage (LAA) occluder devices in the weeks following implantation in two large registry studies of patients with atrial ...

PHOENIX -- A novel transcatheter device that twists the left atrial appendage (LAA) closed from the inside appeared safe in first-in-human results. Among 15 atrial fibrillation patients who received ...

Guangdong Pulse Medical Technology Co. Ltd. received marketing approval from China’s NMPA for its left atrial appendage (LAA) closure product called the Leftear occluder system.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and remains a significant contributor to morbidity and mortality worldwide. A central focus of current research is the left ...

ROCHESTER, MN – The PREVAIL study, a clinical trial evaluating the safety of the Watchman (Boston Scientific) left atrial appendage (LAA) closure device in the treatment of patients with nonvalvular ...

TCT 1508: Double, Double Toil and Trouble: Combined Aortic and Mitral Valve-in-Valve Procedure With Double Balloon Valve Fracture and Iatrogenic ASD Requiring Emergency Percutaneous Closure Receive ...